Production (Stage)
Relmada Therapeutics, Inc.
RLMD
$0.6827
-$0.0146-2.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.88% | 14.13% | -22.28% | 18.60% | 13.26% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.82% | -7.39% | 5.57% | -13.01% | -13.68% |
| Change in Net Operating Assets | -265.03% | 217.82% | 6.39% | -536.93% | -88.95% |
| Cash from Operations | -105.32% | 47.17% | -25.59% | -1.74% | -27.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 35.38% | -29.72% | 15.19% | 39.33% | 29.94% |
| Cash from Investing | 35.38% | -29.72% | 15.19% | 39.33% | 29.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -92.52% | -- | 100.00% | 74.62% |
| Cash from Financing | -- | -92.52% | -- | -100.00% | 325.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -214.08% | 493.89% | -180.21% | 127.25% | -5.74% |